1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Gastric Cancer - Pipeline Review, H2 2016

Gastric Cancer - Pipeline Review, H2 2016

  • October 2016
  • -
  • Global Markets Direct
  • -
  • 963 pages

Gastric Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H2 2016, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 68, 68, 7, 65, 6 and 2 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 5, 3, 7 and 1 molecules, respectively for Gastric Cancer.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Gastric Cancer - Pipeline Review, H2 2016
Table of Contents
Table of Contents 2
Introduction 9
Gastric Cancer Overview 10
Therapeutics Development 11
Gastric Cancer - Therapeutics under Development by Companies 13
Gastric Cancer - Therapeutics under Investigation by Universities/Institutes 24
Gastric Cancer - Pipeline Products Glance 25
Gastric Cancer - Products under Development by Companies 29
Gastric Cancer - Products under Investigation by Universities/Institutes 45
Gastric Cancer - Companies Involved in Therapeutics Development 46
Gastric Cancer - Therapeutics Assessment 184
Drug Profiles 214
Gastric Cancer - Dormant Projects 911
Gastric Cancer - Discontinued Products 924
Gastric Cancer - Product Development Milestones 928
Appendix 935

List of Tables
Number of Products under Development for Gastric Cancer, H2 2016 38
Number of Products under Development for Gastric Cancer - Comparative Analysis, H2 2016 39
Number of Products under Development by Companies, H2 2016 40
Number of Products under Development by Companies, H2 2016 (Contd..1) 41
Number of Products under Development by Companies, H2 2016 (Contd..2) 42
Number of Products under Development by Companies, H2 2016 (Contd..3) 43
Number of Products under Development by Companies, H2 2016 (Contd..4) 44
Number of Products under Development by Companies, H2 2016 (Contd..5) 45
Number of Products under Development by Companies, H2 2016 (Contd..6) 46
Number of Products under Development by Companies, H2 2016 (Contd..7) 47
Number of Products under Development by Companies, H2 2016 (Contd..8) 48
Number of Products under Development by Companies, H2 2016 (Contd..9) 49
Number of Products under Development by Companies, H2 2016 (Contd..10) 50
Number of Products under Investigation by Universities/Institutes, H2 2016 51
Comparative Analysis by Late Stage Development, H2 2016 52
Comparative Analysis by Clinical Stage Development, H2 2016 53
Comparative Analysis by Early Stage Development, H2 2016 54
Comparative Analysis by Unknown Stage Development, H2 2016 55
Products under Development by Companies, H2 2016 56
Products under Development by Companies, H2 2016 (Contd..1) 57
Products under Development by Companies, H2 2016 (Contd..2) 58
Products under Development by Companies, H2 2016 (Contd..3) 59
Products under Development by Companies, H2 2016 (Contd..4) 60
Products under Development by Companies, H2 2016 (Contd..5) 61
Products under Development by Companies, H2 2016 (Contd..6) 62
Products under Development by Companies, H2 2016 (Contd..7) 63
Products under Development by Companies, H2 2016 (Contd..8) 64
Products under Development by Companies, H2 2016 (Contd..9) 65
Products under Development by Companies, H2 2016 (Contd..10) 66
Products under Development by Companies, H2 2016 (Contd..11) 67
Products under Development by Companies, H2 2016 (Contd..12) 68
Products under Development by Companies, H2 2016 (Contd..13) 69
Products under Development by Companies, H2 2016 (Contd..14) 70
Products under Development by Companies, H2 2016 (Contd..15) 71
Products under Investigation by Universities/Institutes, H2 2016 72
Gastric Cancer - Pipeline by 3SBio Inc., H2 2016 73
Gastric Cancer - Pipeline by AB Science SA, H2 2016 74
Gastric Cancer - Pipeline by AbbVie Inc, H2 2016 75
Gastric Cancer - Pipeline by AbGenomics International, Inc., H2 2016 76
Gastric Cancer - Pipeline by ADC Therapeutics Sarl, H2 2016 77
Gastric Cancer - Pipeline by Advaxis, Inc., H2 2016 78
Gastric Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016 79
Gastric Cancer - Pipeline by Agenus, Inc., H2 2016 80
Gastric Cancer - Pipeline by Almac Discovery Limited, H2 2016 81
Gastric Cancer - Pipeline by Alteogen Inc., H2 2016 82
Gastric Cancer - Pipeline by Ambrx, Inc., H2 2016 83
Gastric Cancer - Pipeline by Amgen Inc., H2 2016 84
Gastric Cancer - Pipeline by arGEN-X BV, H2 2016 85
Gastric Cancer - Pipeline by Asana BioSciences, LLC, H2 2016 86
Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016 87
Gastric Cancer - Pipeline by Astellas Pharma Inc., H2 2016 88
Gastric Cancer - Pipeline by AstraZeneca Plc, H2 2016 89
Gastric Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2016 90
Gastric Cancer - Pipeline by Athenex, Inc., H2 2016 91
Gastric Cancer - Pipeline by Azaya Therapeutics, Inc., H2 2016 92
Gastric Cancer - Pipeline by Basilea Pharmaceutica Ltd., H2 2016 93
Gastric Cancer - Pipeline by Bayer AG, H2 2016 94
Gastric Cancer - Pipeline by BeiGene, Ltd., H2 2016 95
Gastric Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016 96
Gastric Cancer - Pipeline by Bionovis SA, H2 2016 97
Gastric Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 98
Gastric Cancer - Pipeline by Boston Biomedical, Inc., H2 2016 99
Gastric Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 100
Gastric Cancer - Pipeline by Calithera Biosciences, Inc., H2 2016 101
Gastric Cancer - Pipeline by Cancer Prevention Pharmaceuticals, Inc., H2 2016 102
Gastric Cancer - Pipeline by Celgene Corporation, H2 2016 103
Gastric Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016 104
Gastric Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2016 105
Gastric Cancer - Pipeline by Celltrion, Inc., H2 2016 106
Gastric Cancer - Pipeline by Celon Pharma Sp. z o.o., H2 2016 107
Gastric Cancer - Pipeline by Cerulean Pharma, Inc., H2 2016 108
Gastric Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016 109
Gastric Cancer - Pipeline by Curaxys, S.L., H2 2016 110
Gastric Cancer - Pipeline by DAE HWA Pharmaceutical Co., Ltd., H2 2016 111
Gastric Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 112
Gastric Cancer - Pipeline by Debiopharm International SA , H2 2016 113
Gastric Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016 114
Gastric Cancer - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016 115
Gastric Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 116
Gastric Cancer - Pipeline by Eddingpharm, H2 2016 117
Gastric Cancer - Pipeline by EirGenix Inc., H2 2016 118
Gastric Cancer - Pipeline by Eli Lilly and Company, H2 2016 119
Gastric Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2016 120
Gastric Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 121
Gastric Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2016 122
Gastric Cancer - Pipeline by Frost Biologic, Inc., H2 2016 123
Gastric Cancer - Pipeline by Galena Biopharma, Inc., H2 2016 124
Gastric Cancer - Pipeline by Genelux Corporation, H2 2016 125
Gastric Cancer - Pipeline by Genentech, Inc., H2 2016 126
Gastric Cancer - Pipeline by Gilead Sciences, Inc., H2 2016 127
Gastric Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 128
Gastric Cancer - Pipeline by GlycoNex Inc., H2 2016 129
Gastric Cancer - Pipeline by Glycotope GmbH, H2 2016 130
Gastric Cancer - Pipeline by Green Cross Corporation, H2 2016 131
Gastric Cancer - Pipeline by Halozyme Therapeutics, Inc., H2 2016 132
Gastric Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 133
Gastric Cancer - Pipeline by Horizon Pharma Plc, H2 2016 134
Gastric Cancer - Pipeline by Hutchison MediPharma Limited, H2 2016 135
Gastric Cancer - Pipeline by Ignyta, Inc., H2 2016 136
Gastric Cancer - Pipeline by Immunomedics, Inc., H2 2016 137
Gastric Cancer - Pipeline by Imugene Limited, H2 2016 138
Gastric Cancer - Pipeline by Incyte Corporation, H2 2016 139
Gastric Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 140
Gastric Cancer - Pipeline by INSYS Therapeutics, Inc., H2 2016 141
Gastric Cancer - Pipeline by Intezyne Technologies, Inc., H2 2016 142
Gastric Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 143
Gastric Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2016 144
Gastric Cancer - Pipeline by Johnson and Johnson, H2 2016 145
Gastric Cancer - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2016 146
Gastric Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 147
Gastric Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 148
Gastric Cancer - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H2 2016 149
Gastric Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 150
Gastric Cancer - Pipeline by LegoChem Biosciences, Inc, H2 2016 151
Gastric Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2016 152
Gastric Cancer - Pipeline by MacroGenics, Inc., H2 2016 153
Gastric Cancer - Pipeline by MaxiVAX SA, H2 2016 154
Gastric Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2016 155
Gastric Cancer - Pipeline by MedImmune, LLC, H2 2016 156
Gastric Cancer - Pipeline by Medivation, Inc., H2 2016 157
Gastric Cancer - Pipeline by Merck and Co., Inc., H2 2016 158
Gastric Cancer - Pipeline by Merck KGaA, H2 2016 159
Gastric Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 160
Gastric Cancer - Pipeline by Mersana Therapeutics, Inc., H2 2016 161
Gastric Cancer - Pipeline by Merus NV, H2 2016 162
Gastric Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 163
Gastric Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2016 164
Gastric Cancer - Pipeline by Molecular Targeting Technologies, Inc., H2 2016 165
Gastric Cancer - Pipeline by MolMed S.p.A., H2 2016 166
Gastric Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2016 167
Gastric Cancer - Pipeline by NeuClone Pty Ltd, H2 2016 168
Gastric Cancer - Pipeline by Novartis AG, H2 2016 169
Gastric Cancer - Pipeline by OBI Pharma, Inc., H2 2016 170
Gastric Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2016 171
Gastric Cancer - Pipeline by Oncobiologics, Inc., H2 2016 172
Gastric Cancer - Pipeline by Oncolys BioPharma Inc, H2 2016 173
Gastric Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016 174
Gastric Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016 175
Gastric Cancer - Pipeline by OncoTherapy Science, Inc., H2 2016 176
Gastric Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 177
Gastric Cancer - Pipeline by Opsona Therapeutics Limited, H2 2016 178
Gastric Cancer - Pipeline by Panacea Biotec Limited, H2 2016 179
Gastric Cancer - Pipeline by Patrys Limited, H2 2016 180
Gastric Cancer - Pipeline by Pfizer Inc., H2 2016 181
Gastric Cancer - Pipeline by Pharma Mar, S.A., H2 2016 182
Gastric Cancer - Pipeline by Puma Biotechnology, Inc., H2 2016 183
Gastric Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016 184
Gastric Cancer - Pipeline by Rgenix, Inc., H2 2016 185
Gastric Cancer - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 186
Gastric Cancer - Pipeline by Richter Gedeon Nyrt., H2 2016 187
Gastric Cancer - Pipeline by Samumed LLC, H2 2016 188
Gastric Cancer - Pipeline by Sanofi, H2 2016 189
Gastric Cancer - Pipeline by Sequella, Inc., H2 2016 190
Gastric Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016 191
Gastric Cancer - Pipeline by Shionogi and Co., Ltd., H2 2016 192
Gastric Cancer - Pipeline by Simcere Pharmaceutical Group, H2 2016 193
Gastric Cancer - Pipeline by Sorrento Therapeutics, Inc., H2 2016 194
Gastric Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 195
Gastric Cancer - Pipeline by Supratek Pharma Inc., H2 2016 196
Gastric Cancer - Pipeline by SynCore Biotechnology Co., Ltd., H2 2016 197
Gastric Cancer - Pipeline by Synovo GmbH, H2 2016 198
Gastric Cancer - Pipeline by Synthon Holdings BV, H2 2016 199
Gastric Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 200
Gastric Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016 201
Gastric Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 202
Gastric Cancer - Pipeline by Takis S.r.l., H2 2016 203
Gastric Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 204
Gastric Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016 205
Gastric Cancer - Pipeline by Transgene SA, H2 2016 206
Gastric Cancer - Pipeline by United BioPharma, Inc., H2 2016 207
Gastric Cancer - Pipeline by Vaxon Biotech, H2 2016 208
Gastric Cancer - Pipeline by XuanZhu Pharma Co., Ltd., H2 2016 209
Gastric Cancer - Pipeline by Zymeworks Inc., H2 2016 210
Assessment by Monotherapy Products, H2 2016 211
Assessment by Combination Products, H2 2016 212
Number of Products by Stage and Target, H2 2016 214
Number of Products by Stage and Mechanism of Action, H2 2016 226
Number of Products by Stage and Route of Administration, H2 2016 238
Number of Products by Stage and Molecule Type, H2 2016 240
Gastric Cancer - Dormant Projects, H2 2016 938
Gastric Cancer - Dormant Projects (Contd..1), H2 2016 939
Gastric Cancer - Dormant Projects (Contd..2), H2 2016 940
Gastric Cancer - Dormant Projects (Contd..3), H2 2016 941
Gastric Cancer - Dormant Projects (Contd..4), H2 2016 942
Gastric Cancer - Dormant Projects (Contd..5), H2 2016 943
Gastric Cancer - Dormant Projects (Contd..6), H2 2016 944
Gastric Cancer - Dormant Projects (Contd..7), H2 2016 945
Gastric Cancer - Dormant Projects (Contd..8), H2 2016 946
Gastric Cancer - Dormant Projects (Contd..9), H2 2016 947
Gastric Cancer - Dormant Projects (Contd..10), H2 2016 948
Gastric Cancer - Dormant Projects (Contd..11), H2 2016 949
Gastric Cancer - Dormant Projects (Contd..12), H2 2016 950
Gastric Cancer - Discontinued Products, H2 2016 951
Gastric Cancer - Discontinued Products (Contd..1), H2 2016 952
Gastric Cancer - Discontinued Products (Contd..2), H2 2016 953
Gastric Cancer - Discontinued Products (Contd..3), H2 2016 954

List of Figures
Number of Products under Development for Gastric Cancer, H2 2016 38
Number of Products under Development for Gastric Cancer - Comparative Analysis, H2 2016 39
Number of Products under Development by Companies, H2 2016 40
Number of Products under Investigation by Universities/Institutes, H2 2016 51
Comparative Analysis by Late Stage Development, H2 2016 52
Comparative Analysis by Clinical Stage Development, H2 2016 53
Comparative Analysis by Early Stage Products, H2 2016 54
Assessment by Monotherapy Products, H2 2016 211
Assessment by Combination Products, H2 2016 212
Number of Products by Top 10 Targets, H2 2016 213
Number of Products by Stage and Top 10 Targets, H2 2016 213
Number of Products by Top 10 Mechanism of Actions, H2 2016 225
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 225
Number of Products by Top 10 Routes of Administration, H2 2016 237
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 237
Number of Products by Top 10 Molecule Types, H2 2016 239
Number of Products by Stage and Top 10 Molecule Types, H2 2016 239

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Rosetta Genomics, Ltd. (ROSG) - Product Pipeline Analysis, 2016 Update

Rosetta Genomics, Ltd. (ROSG) - Product Pipeline Analysis, 2016 Update

  • $ 750
  • Company report
  • August 2016
  • by Global Data

Summary Rosetta Genomics Ltd (RGL) is a biotechnology company that develops next generation diagnostic tests for personalized medicine. The company offers testing services such as cancer origin, next-gen, ...

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Pipeline Review, H2 2016

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • July 2016
  • by Global Markets Direct

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Pipeline Review, H2 2016 Summary ...

Pacific Edge Limited (PEB) - Product Pipeline Analysis, 2016 Update

Pacific Edge Limited (PEB) - Product Pipeline Analysis, 2016 Update

  • $ 750
  • Company report
  • June 2016
  • by Global Data

Summary Pacific Edge Limited (PEB) is a medical diagnostics company that discovers and commercializes diagnostic and prognostic technology for the early detection and monitoring of cancer. The company ...

Coherus Biosciences, Inc. (usa)

January 2016 $ 2750

Oncolytics Biotech, Inc. (canada)

January 2016 $ 2600

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.